Related Experiment Video
Updated: Nov 5, 2025

07:06
Binocular Dynamic Visual Acuity in Eyeglass-Corrected Myopic Patients
Published on: March 29, 2022
2.9K
Prevalence of Visual Acuity Loss or Blindness in the US: A Bayesian Meta-analysis
Abraham D Flaxman1, John S Wittenborn2, Toshana Robalik1
1Institute for Health Metrics and Evaluation, University of Washington, Seattle.
JAMA Ophthalmology
|May 13, 2021
Summary
New estimates reveal over 7 million Americans experience visual acuity loss and over 1 million face blindness. These figures, higher than previous studies, highlight the significant public health impact of vision impairment in the US.
Area of Science:
- Ophthalmology
- Public Health
- Epidemiology
Background:
- Globally, over 250 million people have vision loss.
- In the US, vision loss is feared more than memory, hearing, or speech loss.
- Recent empirical estimates for US visual acuity loss and blindness are lacking.
Purpose of the Study:
- To estimate the prevalence of visual acuity loss and blindness in the US.
- To stratify these estimates by age, sex, race/ethnicity, and US state.
Main Methods:
- Utilized data from the American Community Survey (2017), National Health and Nutrition Examination Survey (1999-2008), and National Survey of Children's Health (2017).
- Included population-based studies (2000-2013) and data from the CDC's Vision and Eye Health Surveillance System.
- Estimated prevalence stratified by demographics and location; data analysis conducted from March 2018 to March 2020.
Main Results:
- In 2017, an estimated 7.08 million people in the US had visual acuity loss.
- Approximately 1.08 million people in the US were living with blindness in 2017.
- 1.62 million with visual acuity loss and 141,000 with blindness were younger than 40 years.
Conclusions:
- This meta-analysis produced significantly higher prevalence estimates than prior studies.
- The findings underscore the substantial public health burden of vision impairment in the United States.
- Modern estimation methods reveal a greater impact of visual acuity loss and blindness.
More Related Videos
Related Concept Videos
Glaucoma: Overview
1.0K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.0K
Photoreceptors and Visual Pathways
7.3K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
7.3K
Angle Closure Glaucoma: Treatment
918
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
918
Open Angle Glaucoma: Treatment
783
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
783

